Drug Trial Radar · NCT02815670
Reversal Dabigatran Anticoagulant Effect With Idarucizumab
Last checked: Nov 20, 2026Latest source record: Apr 14, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1
Actual
Start
Sep 7, 2016
Primary completion
Oct 19, 2019
Study completion Oct 19, 2019
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Jun 28, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The trial objective is to demonstrate the safety of idarucizumab, as assessed by the occurence of patients with drug related adverse events (including immune reactions) and all-cause mortality in paediatric venous thromboembolism patients treated with dabigatran in ongoing clinical trials who require emergency surgery/urgent procedures or patients who have life-threatening or uncontrolled bleeding which requires urgent intervention, when rapid reversal of the anticoagulant effect of dabigatran is needed.
Conditions
- Hemorrhage
Interventions
IdarucizumabDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Drug-related Adverse Events (AEs)Time frame: From vial 1 of Idarucizumab until prematurely discontinued of the trial, up to 25 days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Children Rep.Clin.Hosp of MoH,Cardio Vas.surgery Dept, Kazan
Kazan', Russia
Regional Clin.Hosp.1,Congen.heart defects&child.Cardiol.dept
Tyumen, Russia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.